Stone House Investment Management LLC Boosts Stock Position in Becton, Dickinson and Company $BDX

Stone House Investment Management LLC increased its stake in Becton, Dickinson and Company (NYSE:BDX) by 3,788.9% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 350 shares of the medical instruments supplier’s stock after purchasing an additional 341 shares during the quarter. Stone House Investment Management LLC’s holdings in Becton, Dickinson and Company were worth $60,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC lifted its holdings in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares in the last quarter. Penserra Capital Management LLC increased its holdings in Becton, Dickinson and Company by 394.0% during the 1st quarter. Penserra Capital Management LLC now owns 3,735 shares of the medical instruments supplier’s stock worth $855,000 after acquiring an additional 2,979 shares during the period. Envestnet Asset Management Inc. lifted its stake in Becton, Dickinson and Company by 10.1% in the 1st quarter. Envestnet Asset Management Inc. now owns 1,020,625 shares of the medical instruments supplier’s stock worth $233,784,000 after purchasing an additional 93,926 shares in the last quarter. TD Private Client Wealth LLC boosted its holdings in Becton, Dickinson and Company by 44.6% in the 1st quarter. TD Private Client Wealth LLC now owns 5,210 shares of the medical instruments supplier’s stock valued at $1,193,000 after purchasing an additional 1,607 shares during the period. Finally, U.S. Capital Wealth Advisors LLC grew its position in shares of Becton, Dickinson and Company by 42.6% during the 1st quarter. U.S. Capital Wealth Advisors LLC now owns 1,745 shares of the medical instruments supplier’s stock valued at $400,000 after purchasing an additional 521 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on BDX shares. Morgan Stanley increased their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $211.00 price target on shares of Becton, Dickinson and Company in a report on Thursday, October 16th. Wells Fargo & Company lifted their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an “equal weight” rating in a research report on Friday, August 8th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Hold” and a consensus price target of $205.40.

Insider Transactions at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 1,895 shares of company stock worth $358,995 in the last ninety days. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX opened at $176.22 on Thursday. The stock’s 50-day moving average is $187.35 and its 200 day moving average is $182.59. The stock has a market cap of $50.51 billion, a price-to-earnings ratio of 31.69, a P/E/G ratio of 1.42 and a beta of 0.25. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The firm had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.